Navigation Links
Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
Date:5/31/2009

glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements. These include statements concerning the potential for TELCYTA to treat ovarian cancer, the effectiveness of TELCYTA in combination with PLD and in patients under certain platinum refractory and platinum resistant conditions, and the effectiveness of TELCYTA upon stomatitis and PPE associated with PLD. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including the risks associated with clinical trials and the interpretation of resulting data. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2009. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Telik Announces Preclinical Presentations at AACR Annual Meeting
2. Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance
3. Telik Announces Year-End Financial Release, Conference Call and Webcast
4. Telik Announces Patents on Compounds Related to TELINTRA
5. Telik Announces Preclinical Presentations at AACR Annual Meeting
6. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
7. Lumenis(R) Presents the SlimLine(TM) GI Laser Fiber: The Latest Advancement in Laser Lithotripsy for Gastroenterology
8. Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook
9. AGA Institute presents cutting-edge research during DDW
10. The Pediatric IBD Center at Cedars-Sinai Medical Center Presents Rock-n-Reel 2009 Honoring Alexandra Milchan-Lambert & Scott Lambert
11. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... pathologist Lukas Kenner and his colleagues have developed a ... tissue sections and demonstrate the presence of specific biomarkers ... of the disease and leads to the most suitable ... study, "Two independent pathologists concur with each other only ... developed software offers, for the first time, the option ...
(Date:7/14/2014)... July 14, 2014 Last month Bromell ... their website. The webpage features more detailed information on ... including motorcycles, RVs, ATVs, and boats in the state ... this new feature to the website in order to ... helps encompass the purpose of the website, which is ...
(Date:7/14/2014)... is he who "begins to age". But laboratory biology ... not a synonym of ageing, it is also not ... a badly named physiological process that those who do ... That is the case of Manuel Serrano, from the ... world,s leading experts on senescence, who has just published ...
(Date:7/14/2014)... may buffer some of the adverse health effects of ... researchers from the American Cancer Society, The Cooper Institute, ... the journal Mayo Clinic Proceeding s, and finds ... blood markers associated with cardiovascular disease is markedly less ... has been linked to an increase risk of obesity, ...
(Date:7/14/2014)... Botanica Day Spa announced last month that their ... the day spa in down town Clearwater, FL on ... refreshments will be served as clients are invited to ... and great deals on spa services, including the ... (also known as “facial shaving”) is a simple and ...
Breaking Medicine News(10 mins):Health News:Scientists developed new technology for the diagnosis of cancer cells 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3
... mortality for hospitalized patients, study found , , TUESDAY, Oct. ... hospitalized for pneumonia was one-third lower for those taking ... a Danish study found. , While the findings are ... doctors can prescribe statins as infection fighters, experts said. ...
... Intentional Interference with ... Prospective Business Advantage, CAMBRIDGE, Mass., Oct. ... it had filed an action for injunctive,relief and damages against ... Hemopure, hemoglobin glutamer-250,(bovine), Biopure,s oxygen therapeutic product for human use. ...
... ... Cost Reduction Efforts Continue to Generate Results ... Step for Visian Toric ICL Application to ... FDA, MONROVIA, Calif., Oct. 28 STAAR ...
... disease rises as the joint ailment worsens, research shows ... (RA) may increase the risk of gum disease, a ... link between RA and periodontal disease, a condition where ... from the gums, loss of bony support, and possible ...
... 28 Blue Mountain Quality,Resources, Inc. announced ... Regulatory Asset Manager(R) to satisfy their immediate ... their enterprise-wide,SAP(R) implementation., "Alexion is committed ... in,its manufacturing facilities and other operations," explains ...
... 28 NASA satellite data can,improve forecasts of ... that can,benefit public health managers. Scientists announced the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ), Led by ... Mexico in,Albuquerque, and William Sprigg of the University ...
Cached Medicine News:Health News:Statins Reduced Death Risk From Pneumonia 2Health News:Statins Reduced Death Risk From Pneumonia 3Health News:Biopure Sues National Institutes of Health Official 2Health News:Biopure Sues National Institutes of Health Official 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 2Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 4Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 5Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 6Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 7Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 8Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 9Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 10Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 11Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 12Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 13Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 14Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 15Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 16Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 17Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 18Health News:Rheumatoid Arthritis May Harm Gums 2Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 3
(Date:7/14/2014)... , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on Form ... by Mallinckrodt plc on May 16, 2014 and amended on ... Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, ... on Form S-4 is available on the SEC,s EDGAR system, ...
(Date:7/14/2014)... -- BioAdaptives, Inc. (OTCBB:BDPT) is pleased to announce Mr. ... of President and CEO of the Company.  Mr. Epling ... that licensed its formulation, intellectual properties, and other technologies ... "Mr. Gerald Epling , who has been ... held entity to a public company, has decided to ...
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7BioAdaptives Prepares for Next Step 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: